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Abstract
Background: Dectin-1 is a pattern recognition receptor (PRR) expressed by myeloid cells that specifically recognizes b-1,3
glucan, a polysaccharide and major component of the fungal cell wall. Upon activation, dectin-1 signaling converges, similar
to NOD2, on the adaptor molecule CARD9 which is associated with inflammatory bowel disease (IBD). An early stop codon
polymorphism (c.714T.G) in DECTIN-1 results in a loss-of-function (p.Y238X) and impaired cytokine responses, including
TNF-a, interleukin (IL)-1b and IL-17 upon in vitro stimulation with Candida albicans or b-glucan. The aim of the present study
was to test the hypothesis that the DECTIN-1 c.714T.G (p.Y238X) polymorphism is associated with lower disease
susceptibility or severity in IBD and to investigate the level of dectin-1 expression in inflamed and non-inflamed colon tissue
of IBD patients.
Methodology: Paraffin embedded tissue samples from non-inflamed and inflamed colon of IBD patients and from
diverticulitis patients were immunohistochemically stained for dectin-1 and related to CD68 macrophage staining. Genomic
DNA of IBD patients (778 patients with Crohn’s disease and 759 patients with ulcerative colitis) and healthy controls
(n = 772) was genotyped for the c.714T.G polymorphism and genotype-phenotype interactions were investigated.
Principal Findings: Increased expression of dectin-1 was observed in actively inflamed colon tissue, as compared to non-
inflamed tissue of the same patients. Also an increase in dectin-1 expression was apparent in diverticulitis tissue. No
statistically significant difference in DECTIN-1 c.714T.G allele frequencies was observed between IBD patients and healthy
controls. Furthermore, no differences in clinical characteristics could be observed related to DECTIN-1 genotype, neither
alone, nor stratified for NOD2 genotype.
Conclusions: Our data demonstrate that dectin-1 expression is elevated on macrophages, neutrophils, and other immune
cells involved in the inflammatory reaction in IBD. The DECTIN-1 c.714T.G polymorphism however, is not a major
susceptibility factor for developing IBD.
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Introduction
Inflammatory bowel disease (IBD), is an idiopathic, chronic,
relapsing inflammatory disorder of the gastrointestinal tract. It is
commonly accepted that IBD is caused by an exaggerated cell
mediated immune response to intestinal microbiota in genetically
susceptible individuals[1,2]. IBD mainly involves two distinct
diseases, which show some overlap: Crohn’s disease (CD) and
ulcerative colitis (UC). Genetic susceptibility is more pronounced
in CD compared to UC[3]. Several susceptibility loci for
developing CD have been identified in the past decades including
the NOD2 gene within the IBD1 locus[4]. The established
association of NOD2 (CARD15) with CD emphasizes the important
role of the intestinal microbiota in the pathogenesis of CD, since
NOD2 acts as an intracellular pattern recognition receptor (PRR)
recognizing bacterial peptidoglycans[5,6].
Dectin-1 (CLEC7A) is a pattern-recognition receptor expressed
by myeloid cells which specifically recognizes b-(1,3)-glucan, a
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polysaccharide and component of the fungal cell wall. As a result,
dectin-1 is involved in recognition of fungi such as Candida albicans
and Aspergillus fumigatus. Upon activation, dectin-1 recruits spleen
tyrosine kinase (Syk) which in turn activates NF-kB, requiring the
adaptor molecule Caspase Activating Recruitment Domain 9
(CARD9), a key adaptor for non-Toll Like Receptor (TLR) signal
transduction[7]. Although not the exclusive pathway, CARD9 also
has a critical function in NOD2-mediated activation of the kinases
p38 and Jnk, required for the production of pro-inflammatory
cytokines in innate immune responses to intracellular patho-
gens[8]. LeibundGut-Landmann et al. showed that dectin-1-Syk-
CARD9 signaling induces dendritic cell (DC) maturation and
secretion of pro-inflammatory cytokines like interleukin (IL)-6,
TNF-a, IL-17 and IL-23[9]. Furthermore, Zhernakova et al.
identified CARD9 as a susceptibility locus for IBD[10]. Recently,
the DECTIN-1 polymorphism c.714T.G on chromosome 12p13
has been described, with a transition from a tyrosine to an early
stop codon on amino acid position 238 (p.Y238X)[11]. The
functional consequence of this polymorphism is a complete loss-of-
function, and immune cells expressing this truncated protein
produce significantly less cytokines, including TNF-a, IL-1b and
IL-17, upon in vitro stimulation with b-glucan or Candida
albicans[12].
Th17 responses are considered to be involved in the
pathogenesis of auto-immune diseases. This T cell subset appears
to play a role in the etiology of CD since IL-17 is up-regulated in
the intestine of IBD patients[13]. Interestingly, both NOD2 and
dectin-1 are shown to be capable of inducing Th17 responses after
activation[9,14]. In this respect, the DECTIN-1 c.714T.G
polymorphism could influence the Th17 response towards fungi
such as Candida albicans, a commensal microorganism of the
gastrointestinal tract. Candida albicans is also one of the immuno-
gens for developing antibodies against Saccharomyces cerevisiae
(ASCA), which are regularly observed in patients with CD[15,16].
Taking together the data from various studies, a dysregulation
of the immune response to the commensal Candida albicans through
dectin-1 and IL-17 release might play a role in the pathogenesis of
CD.
As stated above, activation of NOD2 and dectin-1 leads to
signaling through a shared pathway (CARD9). The importance of
this pathway in CD is demonstrated by the fact that mutations in
NOD2 and CARD9 and the presence of circulating ASCA, are
associated with CD. Since the c.714T.G polymorphism within
DECTIN-1 results in a loss of function, we hypothesized that this
polymorphism could be potentially protective against developing
IBD. Therefore, we aimed to elucidate the role of the DECTIN-1
c.714T.G (p.Tyr238X) polymorphism in patients with IBD,
focusing on the occurrence and the clinical severity of IBD.
Methods
Patients
Patients with a diagnosis of IBD were recruited from the
outpatient clinics of three university hospitals in the Netherlands:
Radboud University Nijmegen Medical Centre (CD: n= 161, UC:
n= 212), VU University Medical Centre Amsterdam (CD:
n= 177, UC: n= 148) and the University Medical Centre
Groningen (CD: n= 308, UC: n= 214), and one regional hospital:
St. Anna Hospital, Geldrop (CD: n= 132, UC: n= 185). Healthy
controls were recruited at the Radboud University Nijmegen
Medical Centre and at the University Medical Centre Groningen
(n = 772).
Diagnosis of IBD was based on accepted clinical, endoscopic,
radiological and histological findings[17]. Clinical data on patients
were retrieved by retrospective collection from patients’ clinical
charts. Clinical data on patients from the VU University Medical
Centre were collected prospectively. The following data were
obtained from patients with CD: age, age at diagnosis, gender,
familial or sporadic IBD, disease localization and behavior of
disease (according to the Vienna classification[18]), extra-intestinal
manifestations, peri-anal disease, and surgery for CD. For patients
with UC, the following data were obtained: age, age at diagnosis,
disease location (according to the Montreal classification[19]),
familial or sporadic IBD, extra intestinal manifestations, surgery
for UC, and occurrence of colorectal cancer.
The ethical committee of region Nijmegen and Arnhem
reviewed and approved the protocol under number CWOM-nr
9804-0100. Verbal informed consent was obtained from each
patient before study participation in agreement with the approval
and all samples were anonymized. Given the fact that all research
data were anonymously collected, at least verbal informed
consent was needed according to national regulations. Therefore,
since written informed consent was not required, no written
informed consent procedure was introduced at time of data
collection.
Genotyping of c.714T.G polymorphism in DECTIN-1
Genomic DNA was isolated from peripheral venous blood using
standard techniques and stored at 4uC. Genotyping of the
c.714T.G (p.Y238X) polymorphism in exon 6 of the DECTIN-1
gene in the patient and healthy control groups from Nijmegen,
Amsterdam and Geldrop was performed by applying the prede-
signed TaqMan SNP assay C_33748481_10 (rs 16910526) on the
7300 ABI Real-Time PCR system (both from Applied Biosystems,
Foster City, CA, USA) using 96-well plates. Genotyping of the IBD
cohort and healthy controls from Groningen, was performed at the
Department of Genetics, UMC Groningen, the Netherlands,
applying the same predesigned TaqMan SNP assay, using the
7900 ABI Real-Time PCR system (Applied Biosystems, Foster
City, CA, USA). The patient and control DNA samples
from Groningen were processed in 384-well plates and each
plate also contained 16 genotyping controls (4 duplicates of
the Centre d’Etudes du Polymorphisme Humain (CEPH) DNA
samples 123002,102405,090203 and 081505). For all polymor-
phisms we obtained .99.8% concordance between our CEPH
genotype data and the CEU (European ancestry) data available
from HapMap.
Genotyping of NOD2 variants
Data on the three common NOD2 variants were available for
CD patients from Groningen and Nijmegen (p.Arg702Trp;
n = 437, p.Gly908Arg; n= 446, p.Leu1007ProfsX2; n= 436).
Genotyping of these three NOD2 variants (c.2104C.T
(p.Arg702Trp), c.2722G.C (p.Gly908Arg), c.3019_3020insC
(p.Leu1007ProfsX2)) has been described before[20].
Immunohistochemical staining
Dectin-1 and CD68 protein expression were evaluated by
immunohistochemical staining in paraffin embedded normal and
inflamed colon tissue of five IBD patients and 4 patients with
diverticulitis, all homozygous for the DECTIN-1 wild-type allele
(T/T). The applied primary antibodies were a monoclonal mouse-
anti-human dectin-1 antibody (MAB 1859, purchased from R&D
Biosystems, Minneapolis, MN, USA), used in a concentration of
5 mg/ml and a monoclonal mouse-anti-human antibody against
CD68 (MCA1815T, purchased from AbD Serotec, Oxford, UK)
which was diluted 100 times before use. After overnight incubation
with the primary antibody, the tissue sections were incubated for
DECTIN-1 c.714T.G in IBD
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1 hour with a secondary antibody after washing with PBS.
Subsequently the staining was visualized by applying ABC
complex and DAB solution. Sections were counterstained with
haematoxylin.
Statistics
Statistical analysis was performed by using SPSS statistical
software, version 16.0 (SPSS Inc., Chicago, IL). Controls and IBD
patients were tested for Hardy Weinberg equilibrium. Allele
frequencies were compared between patients and controls using
the x2 test. P-values were obtained by comparing individuals
carrying at least one DECTIN-1 G allele (G/G genotype and T/G
genotype) with wild-type individuals (T/T genotype). Continuous
variables were compared using Student t-tests. Strength of
association between genotype and phenotype is given as odds
ratio with 95% confidence interval (CI). Statistical interaction
between NOD2 variants and the c.714T.G polymorphism
regarding clinical characteristics, was investigated by comparing
patients carrying a NOD2 susceptibility allele in combination with
carrying one or two copies of the DECTIN-1 G allele, to patients
not bearing any of these NOD2 or DECTIN-1 minor alleles. This
combined analysis for c.714T.G and NOD2 was performed for
each of the three NOD2 susceptibility alleles. A P-value ,0.05 was
considered significant.
Results
Protein expression of dectin-1 in intestinal tissue
Dectin-1 and CD68 staining was performed on matched
intestinal tissue samples from five IBD patients, either inflamed
or non-inflamed, as depicted in Figure 1 and 2. Dectin-1
expression is mainly present on macrophages as showed by
staining for CD68 (Figure 1). Furthermore, dectin-1 also appears
to be weakly expressed on neutrophils, the membrane of
endothelial and epithelial cells and in the submucosal neuronal
plexus of Meissner (not shown). Dectin-1 appeared to be up-
regulated within inflamed colon tissue due to increased expression
of dectin-1 on inflammatory cells and increased influx of
inflammatory cells (Figure 1). In order to test whether this
increased expression of dectin-1 is IBD specific, additional staining
was performed on matched intestinal tissue samples from 4
patients with diverticulitis. As shown in Figure 2, increased
expression of dectin-1 was also observed in patients with severe
diverticulitis compared to mild diverticulitis. As is true for patients
with IBD, expression of dectin-1 is mainly present on macrophages
as shown by CD68 staining.
Distribution of the DECTIN-1 c.714T.G polymorphism in
IBD patients and healthy controls
Characteristics of the study population and healthy controls are
depicted in Table 1. Genotype frequencies of healthy controls
were in Hardy Weinberg equilibrium. Carriage of at least one
copy of the G allele of the DECTIN-1 polymorphism was 14% in
the CD, 14% in the UC and 17% in the healthy control group.
The frequency of the G allele was 9.8% in the healthy controls,
8.1% in CD patients and 7.7% in UC patients. Overall, no
significant differences were observed between patients with IBD
and healthy controls regarding allele frequencies of the DECTIN-1
polymorphism. However, a slight trend towards association of
homozygosity for the DECTIN-1 G allele with IBD was observed
(G allele frequency of 1.0% in healthy controls vs. 0.5–0.6% in CD
and UC, Table 1).
Figure 1. Representative immunohistochemical staining of DECTIN-1 and CD-68 in inflamed and non-inflamed intestine of the
same specimen in Crohn’s disease (2506magnified). Macrophages are present in non-inflamed intestinal tissue but are present in increased
numbers in inflamed tissue (pictures A and C). The expression of DECTIN-1 is increased in inflamed intestinal tissue compared to non-inflamed
intestinal tissue (pictures B and D).
doi:10.1371/journal.pone.0007818.g001
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Correlation of the DECTIN-1 c.714T.G polymorphism
with clinical characteristics of IBD patients
Patients with CD carrying one or two copies of the DECTIN-1
G allele were compared to patients with the wild-type genotype T/
T with regard to age at diagnosis, gender, family history of IBD,
localization of disease and disease behavior, extra intestinal
and peri-anal disease and surgery related to CD (Table 2).
Patients with UC were likewise compared according to the
DECTIN-1 genotypes regarding age at diagnosis, gender, locali-
zation of disease, extra-intestinal disease, development of malig-
nancies, surgery related to UC and a positive family history for
IBD (Table 3). No statistical significant associations were ob-
served between the c.714T.G polymorphism and specific
phenotypes.
The DECTIN-1 c.714T.G polymorphism stratified by
NOD2 status and clinical characteristics of IBD patients
CD patients carrying one or two copies of the G allele of the
DECTIN-1 gene were stratified by NOD2 status. A NOD2 risk
genotype was defined as carrying at least one of the three common
NOD2 disease susceptibility alleles (c.2104C.T (p.Arg702Trp),
c.2722G.C (p.Gly908Arg), c.3019_3020insC (p.Leu1007ProfsX2)).
Combinations of NOD2 risk carriers and DECTIN-1 c.714T.G
carriers were compared to patients not bearing any of these NOD2 or
DECTIN-1 minor alleles, regarding clinical characteristics. No
statistical significant interaction between DECTIN-1 c.714T.G
and one of the NOD2 variants was observed (data not shown).
Discussion
Signaling through dectin-1, known for its recognition of the
fungal component b-glucan, has been described to be involved in
several immunological pathways. Dectin-1 amplifies pro-inflam-
matory cytokine production induced by TLR2 and TLR4, and
primes Th1, Th17 and cytotoxic T cell responses induced by
dendritic cells[9,21]. The DECTIN-1 c.714T.G polymorphism
results in a loss-of-function of dectin-1, and we hypothesized that
this polymorphism could be potentially protective in either the
susceptibility to or the disease severity of IBD.
Figure 2. Representative immunohistochemical staining of dectin-1 and CD68 in mild and severe diverticulitis (2506magnified).
Macrophages are present in intestinal tissue of mild diverticulitis but are present in increased numbers in severe diverticulitis (pictures A and B). Also,
the expression of dectin-1 is increased in severe diverticulitis compared to mild diverticulitis (pictures C and D).
doi:10.1371/journal.pone.0007818.g002
Table 1. Distribution of genotypes of wild-type, heterozygous and homozygous individuals for the c.714T.G polymorphism.
DECTIN-1 status Controls Crohn’s disease P-value* Ulcerative colitis P-value*
Total cohort, number 772 (100%) 778 (100%) 759 (100%)
T/T 642 (83.2%) 667 (85.7%) 0.16 655 (86.3%) 0.09
T/G 122 (15.8%) 106 (13.6%) 100 (13.2%)
G/G 8 (1.0%) 5 (0.6%) 4 (0.5%)
Values are presented as absolute numbers (percentages).
*Healthy controls versus patients with IBD; carriers of the mutant allele (T/G and G/G) were compared to wild-types (T/T).
doi:10.1371/journal.pone.0007818.t001
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As shown by immunohistochemical staining of intestinal tissue,
dectin-1 is mainly present on macrophages, but also weakly on
epithelial and endothelial layers of the intestine. Similar findings in
mice have been demonstrated by Wong and co-workers, who
demonstrated that dectin-1 is mainly expressed on populations of
myeloid cells (monocyte/macrophage and neutrophil lineag-
es)[22]. In addition, they demonstrated that dectin-1 is also
expressed in the Peyer’s patches and along the lamina propria of
the mouse intestine[23,24]. Interestingly, dectin-1 expression
appeared to be elevated in inflamed intestinal tissue compared
to normal tissue, due to the increased infiltration of immune cells
and increased dectin-1 expression on the cell membrane of
immune cells.
However, intestinal expression of dectin-1 did not appear to be
disease specific but rather dependent on influx of macrophages. In
fact, expression of dectin-1 was also present in intestinal samples
from patients with diverticulitis. Increased infiltration of macro-
phages in severe diverticulitis showed an increased expression of
Table 2. Association between DECTIN-1 genotypes and clinical characteristics in a subset of Crohn’s disease patients from whom
detailed phenotypic data were available (N = 778).
Characteristic Total cohort CD (%) T/T (%) T/G (%) G/G (%) Odds ratio* 95% CI*
Mean age at diagnosis, yr (SD) 29.58 (612.29) 29.37 (612.64) 30.76 (617.32)
Male gender (%) 261 (33.5) 222/667 (33.3) 37/106 (34.9) 2/5 (40.0)
Familial IBD (N= 631) 131 (20.8) 107/588 (20.3) 24/101 (24.0) 0/5 (0) 1.32 0.78 2.17
Localization (Vienna
Classification) (%) (n = 778)
L1: ileum 196 164/667 (24.6) 32/106 (30.2) 0/0 (0) 1.24 0.80 1.94
L2: colon 194 163 (24.2) 28 (26.4) 3 (60.0) 1.20 0.76 1.88
L3: ileocolonic 388 340 (51.0) 46 (43.4) 2 (40.0) 0.73 0.49 1.10
L4: upper disease 43 36 (5.4) 7 (6.6) 0 (0) 1.18 0.51 2.72
Disease behavior (Montreal
classification) (%) (n = 776)
B1: non structuring, non
penetrating (%)
291 (37.5) 250/665 (37.6) 39/106 (36.8) 2/5 (40.0) 0.97 0.64 1.47
B2: structuring 215 (27.7) 187 (28.1) 27 (25.5) 1 (20.0) 0.86 0.54 1.37
B3: penetrating 270 (34.8) 228 (34.3) 40 (37.7) 2 (40.0) 1.16 0.77 1.77
Extraintestinal disease (%)
(n = 750)
151 (20.1) 125/642 (19.5) 26/103 (25.2) 0/5 (0) 1.31 0.81 2.13
Perianal disease (%) (n = 643) 177 (27.5) 149/548 (27.2) 26/90 (28.9) 2/5 (40.0) 1.12 0.69 1.81
Surgery (n = 774) 411 (53.1) 355/664 (53.5) 54/105 (51.4) 2/5 (40.0) 0.90 0.60 1.35
Values are presented as absolute numbers (percentages).
*Carriers of the mutant allele (T/G and G/G) were compared to wild-types (T/T).
doi:10.1371/journal.pone.0007818.t002
Table 3. Association between DECTIN-1 genotypes and clinical characteristics in a subset of ulcerative colitis patients from whom
detailed phenotypic data were available (N = 759).
Characteristic Total cohort UC (%) T/T (%) T/G (%) G/G (%) Odds ratio* 95% CI*
Age at diagnosis (SD) 36.3 (614.4) 33.9 (612.9) 35.5 (610.4)
Male gender 401 (52.8) 346/655 (52.8) 52/100 (52.0) 3/4 (75.0)
Localization (Montreal)
(n = 721)
E1 (Proctitis) 124 (17.2) 110/623 (17.7) 14/95 (14.7) 0/3 (0) 0.78 0.43 1.42
E2 (Left sided) 245 (44.0) 212 (34.0) 33 (34.7) 0 (0) 0.98 0.63 1.54
E3 (Extended/pancolitis) 352 (48.8) 301 (48.3) 48 (50.5) 3 (100) 1.16 0.76 1.79
Extraintestinal disease
(n = 228)
42 (18.4) 33/183 (18.0) 8/43 (18.6) 1/2 (50) 1.14 0.50 2.59
Surgery (n = 759) 145 (19.1) 120/655 (18.3) 24/100 (24.0) 1/4 (25.0) 1.41 0.86 2.31
Malignancy (n = 384) 2 (0.5) 1/329 (0.3) 1/53 (1.9) 0/2 (0) 6.07 0.37 98.57
Family diagnosis of IBD
(n = 547)
81 (14.8) 72/472 (15.3) 9/72 (12.5) 0/3 (0) 0.76 0.36 1.59
Values are presented as absolute numbers (percentages).
*Carriers of the mutant allele (T/G and G/G) were compared to wild-types (T/T).
doi:10.1371/journal.pone.0007818.t003
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dectin-1, compared to mild diverticulitis which is accompanied by
less infiltration of macrophages.
Cohorts of CD (n=778) and UC (n=759) patients were screened
for the DECTIN-1 c.714T.G polymorphism and compared to a
group of healthy subjects (n=772). Subsequently, these genetic data
were correlated with clinical parameters reflecting disease severity.
This analysis revealed no statistical significant association between the
prevalence of the DECTIN-1 c.714G allele and IBD, neither in
disease occurrence nor in disease severity. However, one can observe
that homozygous individuals bearing the DECTIN-1 polymorphism
were twice as frequent in healthy controls compared to IBD patients.
This may suggest that complete absence of dectin-1 function could
protect against IBD. It is important to realize that the only two dectin-
1 isoforms capable of binding b-glucans (isoforms A and B) are
structurally equally affected by the DECTIN-1 c.714T.G polymor-
phism[25]. The occurrence of splicing isoforms with residual function
could therefore be excluded. The potential mechanism of protection
are likely to include the lower production of pro-inflammatory
cytokines, including IL-17, in the individuals with defective dectin-1.
In these series, statistical power to preclude any functional difference
is insufficient due to the low prevalence of homozygous individuals.
Additional studies in homozygous and heterozygous subpopulations
are needed to confirm the reported observations.
All together, the reports of the association of mutations within
NOD2 and CARD9 in patients with CD, the presence of ASCA,
and the shared signaling pathway of dectin-1 and NOD2, points
toward a possible link between NOD2 and dectin-1[26]. Since
mutations in NOD2 in CD patients are associated with ileal
involvement and increased need for surgery and stricturing
disease[27], a potential interaction between NOD2 mutations
and the DECTIN-1 c.714T.G polymorphism with regard to
phenotypical characteristics was investigated. However, no
statistical interaction could be demonstrated (data not shown).
Our data demonstrate that dectin-1 expression is elevated on
macrophages, neutrophils, and other immune cells involved in the
inflammatory reaction in IBD. The DECTIN-1 c.714T.G
polymorphism is not a major susceptibility factor for protection
against IBD, although a trend towards a lower frequency of the
polymorphism in CD and UC cohorts was observed, in particular
in the number of individuals homozygous for the DECTIN-1
polymorphism. These genetic findings warrant further investiga-
tion of this pathogenetic pathway.
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